ArticlePLoS neglected tropical diseases2020
Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018.
Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 2 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- Prevalence and outcomes of malaria as co-infection among patients with human African trypanosomiasis: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Chemotherapy for second-stage human African trypanosomiasis: drugs in use.The Cochrane database of systematic reviews · 2021Pooled it
- Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study.Clinical pharmacokinetics · 2023Trial
- Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.PLoS neglected tropical diseases · 2021Trial
- Immunoinformatics Approach for the Designing of a Novel mRNA Vaccine Candidate Against Trypanosoma brucei.Acta parasitologica · 2026Article
- Friends or foes: Unraveling the tsetse fly-Spiroplasma symbiosis.PLoS neglected tropical diseases · 2026Review
- Transmission and cost-effectiveness modelling to estimate the progress towards elimination and future strategy optimisation for gambiense human African trypanosomiasis in Uganda.BMC infectious diseases · 2026Article
- Global, regional, and national disease burden of arthropod-borne diseases: Projections to 2030 based on the global burden of disease study 2021.PLoS neglected tropical diseases · 2026Article
- Ruthenium-Catalyzed CH Alkenylation of Trypanocidal Naphthoquinones: A Mechanistic Benchmarking Study.ChemistryOpen · 2026Article
- Control of Human African Trypanosomiasis in the Nola-Bilolo Focus, Central African Republic, 2020-2024: Outcome of Capacity Building, Improved Diagnosis and Treatment.Journal of parasitology research · 2026Article
- Measuring elimination of gambiense human African trypanosomiasis: a comparison of deceptively different metrics.Parasites & vectors · 2025Article
- Article
- Pharmacokinetics of Racemic Eflornithine in Human Plasma and Cerebrospinal Fluid: Clinical Perspectives for L-eflornithine Against Human African Trypanosomiasis.The AAPS journal · 2025Article
- Uncovering the Unusual Inhibition Mechanism of a Trypanosome Alternative Oxidase Inhibitor Displaying Broad-Spectrum Activity against African Animal Trypanosomes.Journal of medicinal chemistry · 2025Article
- Comparative genomics and transcriptomics of theResearch square · 2025Article
- Prevalence and Risk Factor Analysis of Bovine Trypanosoma Infection in Cattle across Three Egyptian Governorates.Acta parasitologica · 2025Article
- Current state and future directions of interventions for neglected tropical diseases.Nature human behaviour · 2025Review
- Bold strides towards the elimination of gambiense human African trypanosomiasis (gHAT) as a public health problem-A case study of Angola.PLoS neglected tropical diseases · 2025Review
- The STROGHAT study protocol: An intervention study to evaluate safety, effectiveness and feasibility of treating gambiense HAT seropositive subjects with acoziborole.Open research Europe · 2025Article
- Roles of cytokines in modulatingFrontiers in parasitology · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2012 human African trypanosomiasis (HAT), also known as sleeping sickness, was targeted for elimination as a public health problem, set to be achieved by 2020. The World Health Organization (WHO) provides here the 2018 update on the progress made toward that objective. Global indicators are reviewed, in particular the number of reported cases and the areas at risk. Recently developed indicators for the validation of HAT elimination at the national level are also presented. METHODOLOGY/PRINCIPAL
findingsWith 977 cases reported in 2018, down from 2,164 in 2016, the main global indicator of elimination is already well within the 2020 target (i.e. 2,000 cases). Areas at moderate or higher risk (i.e. ≥ 1 case/10,000 people/year) are also steadily shrinking (less than 200,000 km2 in the period 2014-2018), thus nearing the 2020 target [i.e. 90% reduction (638,000 km2) from the 2000-2004 baseline (709,000 km2)]. Health facilities providing diagnosis and treatment of gambiense HAT continued to increase (+7% since the previous survey), with a better coverage of at-risk populations. By contrast, rhodesiense HAT health facilities decreased in number (-10.5%) and coverage. At the national level, eight countries meet the requirements to request validation of gambiense HAT elimination as a public health problem (i.e. Benin, Burkina Faso, Cameroon, Côte d'Ivoire, Ghana, Mali, Rwanda, and Togo), while for other endemic countries more efforts are needed in surveillance, control, or both. CONCLUSIONS/SIGNIFICANCE: The 2020 goal of HAT elimination as a public health problem is within grasp, and eligible countries are encouraged to request validation of their elimination status. Beyond 2020, the HAT community must gear up for the elimination of gambiense HAT transmission (2030 goal), by preparing for both the expected challenges (e.g. funding, coordination, integration of HAT control into regular health systems, development of more adapted tools, cryptic trypanosome reservoirs, etc.) and the unexpected ones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.